マーケットレポート詳細

抗真菌薬：技術および世界市場2026年予測

Antifungal Drugs: Technologies and Global Markets

出版元：BCC Research 　 出版元について
発行年：2021年11月
定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文295ページになります。
商品コード：BCC329

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

抗真菌薬の世界市場規模は2021年に145億ドル、2026年には推計179億ドルへと拡大する見通しです。当レポートでは、抗真菌薬の市場/技術的背景、真菌/抗真菌薬市場の紹介、一般的な環境菌類、抗真菌剤のレビュー、新規/革新的な抗真菌剤：現在の開発、臨床試験および製造パイプライン、各種地域別市場分析(北米、欧州、アジア太平洋、中南米、中東アフリカ)、競合状況、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆市場ダイナミクス

・市場ダイナミクス（ドライバー、障壁）

◆真菌/抗真菌薬市場の紹介

・菌類の紹介
・菌類の分類
・適用範囲：ヒューマンヘルスケア
・人間の真菌性疾患の種類と説明
・人間の真菌感染症に関連する危険因子

◆一般的な環境菌類

・カビとそれに関連する人間の問題
・環境カビが独特の問題である理由
・環境真菌とカビによる健康リスク
・環境カビ

◆抗真菌剤のレビュー

・抗真菌剤の紹介
・抗真菌剤の分類
・全身性抗真菌薬
・局所抗真菌薬
・自然に発生する代替物

◆新規/革新的な抗真菌剤：現在の開発、臨床試験および製造パイプライン

・新しく革新的な抗真菌剤の必要性
・新しい抗真菌剤の開発への戦略的アプローチ
・人工知能ベースのプラットフォームテクノロジー(FungalAi)
・新たなターゲットと分子足場
・開発中の新しい抗真菌薬
・特定企業の製造パイプライン

◆抗真菌薬の世界市場

市場収益分析
地域の概要
抗真菌薬の治療と技術の主な開発/動向
・処方抗真菌薬
・OTC抗真菌薬
市場シェア分析
※市場予測データ-2026年掲載

◆抗真菌薬の北米市場

規制及び法的要件
市場ダイナミクス（ドライバー、障壁）
市場分析
・米国、カナダ
（※国地域別にセグメント別、処方抗真菌薬/OTC抗真菌薬のタイプ別の細分化データ掲載）
市場シェア分析
※市場予測データ-2026年掲載

◆抗真菌薬の欧州市場

規制及び法的要件
市場ダイナミクス（ドライバー、障壁）
市場分析
・ドイツ、英国、フランス、イタリア
・スペイン、ベネルクス、スカンジナビア
・その他欧州
（※国地域別にセグメント別、処方抗真菌薬/OTC抗真菌薬のタイプ別の細分化データ掲載）
市場シェア分析
※市場予測データ-2026年掲載

◆抗真菌薬のアジア太平洋市場

規制及び法的要件
市場ダイナミクス（ドライバー、障壁）
市場分析
・日本、中国、インド、韓国
・その他アジア太平洋
（※国地域別にセグメント別、処方抗真菌薬/OTC抗真菌薬のタイプ別の細分化データ掲載）
市場シェア分析
※市場予測データ-2026年掲載

◆抗真菌薬の中南米市場

規制及び法的要件
市場ダイナミクス（ドライバー、障壁）
市場分析
・ブラジル、アルゼンチン、メキシコ、チリ
・その他中南米
（※国地域別にセグメント別、処方抗真菌薬/OTC抗真菌薬のタイプ別の細分化データ掲載）
市場シェア分析
※市場予測データ-2026年掲載

◆抗真菌薬の中東アフリカ市場

規制及び法的要件
市場ダイナミクス（ドライバー、障壁）
市場分析
・中東
・アフリカ
（※地域別にセグメント別、処方抗真菌薬/OTC抗真菌薬のタイプ別のデータ掲載）
市場シェア分析
※市場予測データ-2026年掲載

◆競合状況

・市場シェア分析

◆主要企業プロフィール

・アステラス製薬株式会社
・BAUSCH HEALTH COMPANIES INC.
・BAYER AG
・DR. REDDY’S LABORATORIES LTD.
・GALDERMA PHARMA S.A.
・GILEAD SCIENCES INC.
・GLENMARK PHARMACEUTICALS LTD.
・JANSSEN PHARMACEUTICALS INC. (JOHNSON & JOHNSON)
・LEADIANT BIOSCIENCES INC.
・LUPIN
・MERCK & CO., INC.
・MERZ PHARMA GMBH & CO. KGAA
・MOBERG PHARMA AB
・MYLAN (VIATRIS)
・PERRIGO COMPANY PLC
・PFIZER INC.
・PRESTIGE CONSUMER HEALTHCARE INC.
・SANOFI S.A.
・TARO PHARMACEUTICAL INDUSTRIES LTD.
・TEVA PHARMACEUTICALS INDUSTRIES LTD.

(全295頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

Introduction
Scope of the Report
What’s New in the Report
Methodology and Information Sources
Primary Data and Information Gathering
Secondary Data and Information Gathering
Market Revenue Forecasts
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Global Market Revenue Analysis for Antifungal Drugs
Regional Overview
Market Segment Review

Chapter 3 Market Dynamics

Market Dynamics

Chapter 4 Introduction to Fungi and the Antifungal Drug Market

Introduction to Fungi
Classification of Fungi

Scope of Application: Human Healthcare
Types and Descriptions of Fungi Diseases in Humans

Risk Factors Associated with Human Fungal Infections

Chapter 5 Common Environmental Fungi

Molds and the Human Issues Associated with Them
Why Environmental Mold is a Unique Problem
Health Risks Due to Environmental Fungi and Mold
Environmental Molds

Chapter 6 Review of Antifungal Agents

Introduction to Antifungal Agents
Classification of Antifungal Agents
Systemic Antifungal Drugs

Topical Antifungal Drugs

Naturally Occurring Alternatives

Chapter 7 New and Innovative Antifungals: Current Developments, Clinical Trials and Product Pipelines

The Need for New and Innovative Antifungals
Strategic Approach to the Development of New Antifungal Agents

Artificial Intelligence-Based Platform Technology (FungalAi)
Emerging Targets and Molecular Scaffolds
New Antifungal Drugs in Development

Specific Company Product Pipelines

Chapter 8 Global Market for Antifungal Medications

Introduction
Market Revenue Analysis

Regional Overview
Major Developments and Trends in Antifungal Drug Treatment and Technologies

Market Share Analysis

Chapter 9 North American Market for Antifungal Drugs

Introduction
Regulatory and Legislative Requirements

Market Dynamics

Market Analysis

Market Share Analysis

Chapter 10 European Market for Antifungal Drugs

Introduction
Regulatory and Legislative Requirements

Market Dynamics

Market Analysis

Market Share Analysis

Chapter 11 Asia-Pacific Market for Antifungal Drugs

Introduction
Regulatory and Legislative Requirements

Market Dynamics

Market Analysis

Market Share Analysis

Chapter 12 Latin American Market for Antifungal Drugs

Introduction
Regulatory and Legislative Requirements

Market Dynamics

Market Analysis

Market Share Analysis

Chapter 13 Middle Eastern/African Market for Antifungal Drugs

Introduction
Regulatory and Legislative Requirements

Market Dynamics

Market Analysis

Market Share Analysis

Chapter 14 Competitive Lanscape

Market Share Analysis

Chapter 15 Company Profiles

Introduction
Tier 1: Manufacturers of Prescription Pharmaceuticals

Chapter 16 Appendix A
Tier 1: Large Multinational Companies and Leading Market Share Holders
Company Contact Details
Chapter 17 Appendix B
Tier 2: Entrepreneurial Small and Medium-Sized Enterprises
Company Addresses and Contact Details
Chapter 18 Appendix C
Research Studies in the Design of Antifungal Vaccine Strategy
Chapter 19 Appendix D
Government Regulatory Agencies, Professional Organizations and Regulatory Acronyms
Chapter 20 Appendix E
Acronyms and Terms Commonly Used for Antifungal Drugs and Antifungal Drug Treatments

List of Tables

Summary Table A : Global Market for Antifungal Drugs, by Segment, Through 2026
Summary Table B : Global Market for Antifungal Drugs, by Region, Through 2026
Summary Table C : Global Market for Prescription Antifungal Drugs, by Type, Through 2026
Summary Table D : Global Market for OTC Antifungal Drugs, by Type, Through 2026
Table 1 : Statistics on the Ten Most Significant Invasive Fungal Infections
Table 2 : Major Clinical Manifestations of Histoplasmosis and Associated Risk Factors
Table 3 : Morphologic Features of Fungi and Pseudofungal Infections of Unusual Fungi or of Fungi with Uncertain Etiology
Table 4 : Risk Factors Associated with Human Fungal Infections
Table 5 : Common Symptoms Associated with Environmental Fungi and Molds
Table 6 : Risk Factors Associated with Environmental Fungi and Molds
Table 7 : Common Locations of the Sources of Environmental Molds
Table 8 : History of Antifungal Therapy
Table 9 : Patents on Amphotericin B and Their Expiration Dates
Table 10 : Approved Fluconazole Prescription Products
Table 11 : Patents on Itraconazole and Their Expiration Dates
Table 12 : Patents on Voriconazole and Their Expiration Dates
Table 13 : Approved Voriconazole Prescription Products
Table 14 : Patents on Posaconazole and Their Expiration Dates
Table 15 : Patents on Ketoconazole and Their Expiration Dates
Table 16 : Approved Miconazole OTC Products
Table 17 : International Clotrimazole Brand Names
Table 18 : Approved Generic Prescriptions for Clotrimazole
Table 19 : Patents on Caspofungin and Their Expiration Dates
Table 20 : Patents on Micafungin and Their Expiration Dates
Table 21 : Patents on Anidulafungin and Their Expiration Dates
Table 22 : Antifungal Compounds with Novel Targets in Development
Table 23 : Global Market for Antifungal Drugs, by Segment, Through 2026
Table 24 : Global Market for Antifungal Drugs, by Region, Through 2026
Table 25 : Global Market Shares of Antifungal Drugs, by Region, 2020
Table 26 : North American Market for Antifungal Drugs, by Segment, Through 2026
Table 27 : North American Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 28 : North American Market for OTC Antifungal Drugs, by Type, Through 2026
Table 29 : North American Market for Antifungal Drugs, by Country, Through 2026
Table 30 : U.S. Market for Antifungal Drugs, by Segment, Through 2026
Table 31 : U.S. Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 32 : U.S. Market for OTC Antifungal Drugs, by Type, Through 2026
Table 33 : Canadian Market for Antifungal Drugs, by Segment, Through 2026
Table 34 : Canadian Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 35 : Canadian Market for OTC Antifungal Drugs, by Type, Through 2026
Table 36 : European Market for Antifungal Drugs, by Segment, Through 2026
Table 37 : European Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 38 : European Market for OTC Antifungal Drugs, by Type, Through 2026
Table 39 : European Market for Antifungal Drugs, by Country, Through 2026
Table 40 : German Market for Antifungal Drugs, by Segment, Through 2026
Table 41 : German Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 42 : German Market for OTC Antifungal Drugs, by Type, Through 2026
Table 43 : French Market for Antifungal Drugs, by Segment, Through 2026
Table 44 : French Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 45 : French Market for OTC Antifungal Drugs, by Type, Through 2026
Table 46 : U.K. Market for Antifungal Drugs, by Segment, Through 2026
Table 47 : U.K. Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 48 : U.K. Market for OTC Antifungal Drugs, by Type, Through 2026
Table 49 : Italian Market for Antifungal Drugs, by Segment, Through 2026
Table 50 : Italian Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 51 : Italian Market for OTC Antifungal Drugs, by Type, Through 2026
Table 52 : Spanish Market for Antifungal Drugs, by Segment, Through 2026
Table 53 : Spanish Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 54 : Spanish Market for OTC Antifungal Drugs, by Type, Through 2026
Table 55 : Benelux Market for Antifungal Drugs, by Segment, Through 2026
Table 56 : Benelux Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 57 : Benelux Market for OTC Antifungal Drugs, by Type, Through 2026
Table 58 : Scandinavian Market for Antifungal Drugs, by Segment, Through 2026
Table 59 : Scandinavian Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 60 : Scandinavian Market for OTC Antifungal Drugs, by Type, Through 2026
Table 61 : Rest-of-European Market for Antifungal Drugs, by Segment, Through 2026
Table 62 : Rest-of-European Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 63 : Rest-of-European Market for OTC Antifungal Drugs, by Type, Through 2026
Table 64 : Overview of Healthcare in India
Table 65 : Asia-Pacific Market for Antifungal Drugs, by Segment, Through 2026
Table 66 : Asia-Pacific Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 67 : Asia-Pacific Market for OTC Antifungal Drugs, by Type, Through 2026
Table 68 : Asia-Pacific Market for Antifungal Drugs, by Country, Through 2026
Table 69 : Japanese Market for Antifungal Drugs, by Segment, Through 2026
Table 70 : Japanese Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 71 : Japanese Market for OTC Antifungal Drugs, by Type, Through 2026
Table 72 : Chinese Market for Antifungal Drugs, by Segment, Through 2026
Table 73 : Chinese Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 74 : Chinese Market for OTC Antifungal Drugs, by Type, Through 2026
Table 75 : Indian Market for Antifungal Drugs, by Segment, Through 2026
Table 76 : Indian Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 77 : Indian Market for OTC Antifungal Drugs, by Type, Through 2026
Table 78 : South Korean Market for Antifungal Drugs, by Segment, Through 2026
Table 79 : South Korean Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 80 : South Korean Market for OTC Antifungal Drugs, by Type, Through 2026
Table 81 : Rest of Asia-Pacific Market for Antifungal Drugs, by Segment, Through 2026
Table 82 : Rest of Asia-Pacific Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 83 : Rest of Asia-Pacific Market for OTC Antifungal Drugs, by Type, Through 2026
Table 84 : Latin American Market for Antifungal Drugs, by Segment, Through 2026
Table 85 : Latin American Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 86 : Latin American Market for OTC Antifungal Drugs, by Type, Through 2026
Table 87 : Latin American Market for Antifungal Drugs, by Country, Through 2026
Table 88 : Brazilian Market for Antifungal Drugs, by Segment, Through 2026
Table 89 : Brazilian Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 90 : Brazilian Market for OTC Antifungal Drugs, by Type, Through 2026
Table 91 : Argentinian Market for Antifungal Drugs, by Segment, Through 2026
Table 92 : Argentinian Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 93 : Argentinian Market for OTC Antifungal Drugs, by Type, Through 2026
Table 94 : Mexican Market for Antifungal Drugs, by Segment, Through 2026
Table 95 : Mexican Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 96 : Mexican Market for OTC Antifungal Drugs, by Type, Through 2026
Table 97 : Chilean Market for Antifungal Drugs, by Segment, Through 2026
Table 98 : Chilean Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 99 : Chilean Market for OTC Antifungal Drugs, by Type, Through 2026
Table 100 : Rest of Latin American Market for Antifungal Drugs, by Segment, Through 2026
Table 101 : Rest of Latin American Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 102 : Rest of Latin American Market for OTC Antifungal Drugs, by Type, Through 2026
Table 103 : Number of Saudi Arabian Hospitals and Beds, by Sector and Administrative Region
Table 104 : Middle Eastern/African Market for Antifungal Drugs, by Segment, Through 2026
Table 105 : Middle Eastern/African Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 106 : Middle Eastern/African Market for OTC Antifungal Drugs, by Type, Through 2026
Table 107 : Middle Eastern/African Market for Antifungal Drugs, by Region/Country, Through 2026
Table 108 : Middle Eastern Market for Antifungal Drugs, by Segment, Through 2026
Table 109 : Middle Eastern Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 110 : Middle Eastern Market for OTC Antifungal Drugs, by Type, Through 2026
Table 111 : African Market for Antifungal Drugs, by Segment, Through 2026
Table 112 : African Market for Prescription Antifungal Drugs, by Type, Through 2026
Table 113 : African Market for OTC Antifungal Drugs, by Type, Through 2026
Table 114 : Recent Developments, 2021
Table 115 : Astellas Pharma Inc.: Revenues, 2018-2020
Table 116 : Astellas Pharma Inc.: Key Developments
Table 117 : Bausch Health Companies Inc.: Revenues, by Segment, 2018-2020
Table 118 : Bayer AG: Revenues, 2018-2020
Table 119 : Dr. Reddy's Laboratories: Revenues, 2018-2020
Table 120 : Gilead Sciences Inc.: Revenue & Product, 2018-2020
Table 121 : Lupin: Revenues, 2018-2020
Table 122 : Merck & Co., Inc.: Total Revenues and Revenues, by Antifungal Product Segment, 2018-2020
Table 123 : Perrigo Company PLC 9i: Revenues, 2018-2020
Table 124 : Pfizer Inc.: Revenue, by Drug, 2018-2020
Table 125 : Prestige Consumer Healthcare Inc.: Revenues, 2018-2020
Table 126 : Sanofi S.A.: Revenues, by Segment, 2018-2020
Table 127 : Taro Pharmaceutical Industries Ltd.: Revenues, 2018-2020
Table 128 : Teva Pharmaceutical Industries Ltd.: Revenues, 2018-2020
Table 129 : Tier 1: Major Multinational Medical Device Companies: Contact Details
Table 130 : Tier 2: Entrepreneurial Small and Medium-Sized Enterprises Contact Details
Table 131 : Studies Conducted in the Design of Antifungal Vaccine Strategy
Table 132 : Government Regulatory Agencies, Professional Organizations and Regulatory Acronyms
Table 133 : Commonly Used Acronyms and Terms used for Antifungal Drugs and Antifungal Drug Treatments

List of Figures

Summary Figure A : Global Market for Antifungal Drugs, by Segment, 2020-2026
Summary Figure B : Global Market for Antifungal Drugs, by Region, 2019-2026
Summary Figure C : Global Market for Prescription Antifungal Drugs, by Type, 2020-2026
Summary Figure D : Global Market for OTC Antifungal Drugs, by Type, 2019-2026
Figure 1 : Schematic of Fungi Classification
Figure 2 : Worldwide Distribution of Reported Cases of C. auris, 2018
Figure 3 : Number of Reported Cryptococcosis Cases, 1998-2017
Figure 4 : Global Burden of HIV-Related Cryptococcal Meningitis, by Region
Figure 5 : County-Specific Incidence of Histoplasmosis for the 12 U.S. States for Which Surveillance Data Were Available, 2011-2014
Figure 6 : Timeline of Antifungal Drug Development, 1950-2020
Figure 7 : Sphingolipid Biosynthetic Pathways
Figure 8 : Strategic Approach to the Development of Vaccines for Fungal Infections
Figure 9 : Principle Categories of Vaccines for Fungal Infections
Figure 10 : Mycovia Pharmaceuticals: Current Product Pipeline
Figure 11 : Ibrexafungerp Development Pipeline, 2018-2020
Figure 12 : Global Market for Antifungal Drugs, by Segment, 2019-2026
Figure 13 : Global Market Shares of Antifungal Drugs, by Segment, 2020
Figure 14 : Global Market Shares of Antifungal Drugs, by Region, 2020
Figure 15 : Global Market Shares of Antifungal Drugs, by Company, 2020
Figure 16 : North American Market for Prescription Antifungal Drugs, by Type, 2020
Figure 17 : North American Market for OTC Antifungal Drugs, by Type, 2020
Figure 18 : North American Market Shares of Antifungal Drugs, by Company, 2020
Figure 19 : Mutual Recognition Procedure
Figure 20 : Decentralized Procedure
Figure 21 : European Market for Prescription Antifungal Drugs, by Type, 2020
Figure 22 : European Market for OTC Antifungal Drugs, by Type, 2020
Figure 23 : European Market Shares of Antifungal Drugs, by Company, 2020
Figure 24 : Flowchart of New Drug Development and Approval Process in Japan
Figure 25 : Timeline of the Standard Process of New Drug Approvals in Japan
Figure 26 : Chinese Drug Funding/Reimbursement Approval Procedure
Figure 27 : The Chinese Healthcare System
Figure 28 : Asia-Pacific Market for Prescription Antifungal Drugs, by Type, 2020
Figure 29 : Asia-Pacific Market for OTC Antifungal Drugs, by Type, 2020
Figure 30 : Asia-Pacific Market Shares of Antifungal Drugs, by Company, 2020
Figure 31 : Argentinian Regulatory Drug Approval Procedure, Standard Review 120-240 Business Days for Approval
Figure 32 : Latin American Market for Prescription Antifungal Drugs, by Type, 2020
Figure 33 : Latin American Market for OTC Antifungal Drugs, by Type, 2020
Figure 34 : Latin American Market Shares of Antifungal Drugs, by Company, 2020
Figure 35 : Current Structure of the Healthcare Sectors in Saudi Arabia, 2018
Figure 36 : Middle Eastern/African Market for Prescription Antifungal Drugs, by Type, 2020
Figure 37 : Middle Eastern/African Market for OTC Antifungal Drugs, by Type, 2020
Figure 38 : Middle Eastern/African Market Shares of Antifungal Drugs, by Company, 2020
Figure 39 : Global Market Shares of Antifungal Drugs, by Company, 2020


△ 一番上に戻る